Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation.

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness	Voting Recusals by Section*
Craig T. January (Chair)	University of Wisconsin-Madison—Professor of Medicine, Cardiovascular Medicine Division	None	None	None	None	None	None	None
L. Samuel Wann (Vice Chair)	Columbia St. Mary's Cardiovascular Physicians—Clinical Cardiologist	United Healthcare	None	None	None	None	None	4.1 5.0 6.3 7.3 7.10
Joseph S. Alpert	University of Arizona Health Sciences Center—Professor of Medicine	Bayer Pharmaceuticals (DSMB)‡ Boehringer Ingelheim Daiichi-Sankyo Johnson & Johnson Roche Diagnostics Sanofi-aventis Servier Pharmaceuticals	None	None	None	None	None	4.1 5.0
Hugh Calkins	Johns Hopkins Hospital—Professor of Medicine, Director of Electrophysiology	Atricure Biosense Webster Carecore iRhythm Medtronic† Sanofi-aventis	None	None	None	None	None	5.0 6.3 7.8
Joaquin E. Cigarroa	Oregon Health & Science University—Clinical Professor; Clinical Chief of Cardiology	None	None	None	None	None	None	None
Jamie B. Conti	University of Florida—Professor of Medicine; Division of Cardiovascular Medicine—Chief	None	None	None	Boston Scientific† Medtronic† St. Jude Medical†	Boston Scientific† Medtronic† St. Jude Medical†	None	5.0 6.3 7.8
Patrick T. Ellinor	Massachusetts General Hospital Heart Center, Cardiac Arrhythmia Service—Director	None	None	None	None	None	None	None
Michael D. Ezekowitz	Jefferson Medical College—Professor	ARYx Therapeutics† AstraZeneca Boehringer Ingelheim† Bristol-Myers Squibb† Daiichi-Sankyo† Eisai Johnson & Johnson† Medtronic† Pfizer† Portola† Sanofi-aventis†	None	None	ARYx Therapeutics† Boehringer Ingelheim† Daiichi-Sankyo‡ Portola‡	None	None	4.1 5.0 6.3 7.8
Michael E. Field	University of Wisconsin School of Medicine and Public Health—Assistant Professor of Medicine, Director of Cardiac Arrhythmia Service	None	None	None	None	None	None	None
Katherine T. Murray	Vanderbilt University School of Medicine, Divisions of Clinical Pharmacology and Cardiology—Professor of Medicine	None	None	None	GlaxoSmith Kline‡	None	None	None
Ralph L. Sacco	University of Miami, Miller School of Medicine, Department of Neurology—Chairman	Boehringer Ingelheim‡§	None	None	None	None	None	None
William G. Stevenson	Brigham & Women's Hospital, Cardiac Arrhythmia Program—Director; Harvard Medical School—Professor of Medicine	None	None	Biosense Webster—Needle Ablation Patent‡	Biosense Webster†	None	None	5.0 6.3 7.8
Patrick J. Tchou	Cleveland Clinic Foundation—Section of Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine Heart and Vascular Institute	None	None	None	None	None	None	None
Cynthia M. Tracy	George Washington University Medical Center—Associate Director and Professor of Medicine	None	None	None	None	None	None	None
Clyde W. Yancy	Northwestern University, Feinberg School of Medicine—Magerstadt Professor of Medicine; Division of Cardiology—Chief	None	None	None	None	None	None	None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person's household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

^*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.

^†Indicates significant relationship.

^‡No financial benefit.

^§Dr. Sacco's relationship with Boehringer Ingelheim was added just after final balloting of the recommendations and prior to organizational review, so it was not relevant during the writing or voting stages of the guideline's development.

ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and HRS, Heart Rhythm Society.